Skip to main content
OSCOTECInc. logo

OSCOTECInc. — Investor Relations & Filings

Ticker · 039200 ISIN · KR7039200001 KO Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2022-04-01 Legal Proceedings Report
Country KR South Korea
Listing KO 039200

About OSCOTECInc.

https://oscotec.com/

Oscotec Inc. is a clinical-stage drug discovery and development company focused on translating scientific research into innovative medicines for clinically unmet needs. The company's development pipeline targets various diseases, with a primary focus on immunology, oncology, and neurodegenerative disorders. Key therapeutic areas include rheumatoid arthritis, immune thrombocytopenia, non-small cell lung cancer, acute myeloid leukemia, and Alzheimer's disease. Oscotec specializes in developing novel kinase inhibitors, such as Spleen Tyrosine Kinase (SYK) inhibitors, to address these conditions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(급성골수성 백혈병치료제 (SKI-G-801)에 대한 미국 FDA 임상 1상 시험 결과 - 임상시험결과보고서(Clinical Study Report) 수령)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the results of a Phase 1 clinical trial for a drug (SKI-G-801) and the receipt of a Clinical Study Report. Since this is a formal disclosure of material information regarding clinical trial results, it falls under the category of general regulatory filings (RNS) as it does not fit into specific categories like financial reports, dividends, or director dealings.
2022-04-01 Korean
투자판단관련주요경영사항(신규면역항암제치료제 개발을 위한 기술도입 및 공동연구 계약)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean company Oscotec regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically a technology licensing and joint research agreement for a new immuno-oncology drug. This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market (DART system). Since it details a specific business contract and licensing agreement rather than a financial report, dividend, or management change, it falls under the 'Regulatory Filings' category as a general corporate disclosure.
2022-03-30 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision for a paid-in capital increase (유상증자결정) by Oscotec Inc. It details the issuance of new shares, the purpose of the funds (operating expenses/R&D), the method (third-party allocation), and the specific terms of the convertible preferred shares. This is a formal regulatory filing concerning capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2022-03-25 Korean
정기주주총회결과
AGM Information Classification · 100% confidence The document is an official report of the results from an Annual General Meeting (AGM) held on March 24, 2022. It details the approval of financial statements, dividend resolutions, and the election of directors. This falls under the category of AGM-R (AGM Information/Results).
2022-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from the company OscoTec. It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the auditor (Samduk Accounting Corp). While it contains financial data, it is a standard regulatory disclosure of the audit results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART), this is the official announcement of the audit report submission. FY 2021
2022-03-14 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Oscotec' (주식회사 오스코텍) for the fiscal year ending December 31, 2021. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full narrative annual report, and it is not an announcement (RPA) because it contains the full financial data. FY 2021
2022-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.